26 results about "Lymphoid Tumor" patented technology

We have discovered that allogeneic HSC-engineered human iNKT (3rdHSC-iNKT) cells display potent anti-GvHD functions, by eliminating antigen-presenting myeloid cells in vitro and in xenograft models, without negatively impacting tumor eradication by allogeneic T cells in preclinical models of lymphoma and leukemia. The 3rdHSC-iNKT cells closely resembled the CD4−CD8− / + subsets of endogenous human iNKT cells in phenotype and functionality. Embodiments of the invention harness these discoveries in new methods and materials for alleviating graft versus host disease.

This disclosure relates to methods and compositions for treating cancer including advanced solid tumor, a metastatic solid tumor or lymphoma using an inducible IL-12 prodrug.

This invention relates to the field of image data processing technology, specifically to a method for information fusion between fluorescence images and pathological sections of lymphoma. The method involves acquiring a first image and a second image of a lymphoma tissue sample; the first image is a bright-field image, and the second image is a FISH image. In the first image, the degree of difference between each cell and normal cells, as well as the degree of difference between each tissue boundary and normal tissue boundaries, are analyzed to obtain cell abnormality indices and tissue abnormality indices, respectively. Based on the cell abnormality indices and tissue abnormality indices, a section abnormality index is determined, and the initial block size is adjusted based on the section abnormality index to obtain a target block size. Using the target block size as the block size, a two-stream convolutional network is used to fuse the first image and the second image to obtain a fused image. This invention improves the image fusion effect between FISH images and bright-field images of lymphoma pathological sections.

The invention relates to a triple-effect T cell adapter for targeting T cell lymphoma TRBC1. The invention discloses a TRBC1-targeted triple-effect T cell adapter which is composed of an Fc region, a hinge region, a first Fab arm and a second Fab arm, and a third targeting module is covalently connected to the C end of the Fc region to form a Y-shaped triple-head antibody. The first Fab arm and the second Fab arm are respectively combined with TRBC1 and CD3, and the third Fab arm is combined with CD28 or CD137, so that three functions of tumor recognition, T cell recruitment and co-stimulation amplification are integrated. The two polypeptide chains are heterodimerized through CH3 region button mutation, and correct assembly is ensured. The structure supports module interchange, programmable regulation and control of synergistic signals, significantly enhances TRBC1 positive T cell lymphoma killing, reduces toxicity to normal T cells, has high activity and a wide safety window, and is suitable for preparation of related drugs.

This disclosure relates to methods and compositions for treating cancer, including advanced solid tumors, metastatic solid tumors, or lymphoma, using an inducible IL-12 prodrug. This disclosure relates to compositions and methods for treating cancer using an inducible IL-12 prodrug. This inducible IL-12 prodrug contains attenuated IL-12 and has a longer half-life compared to naturally occurring IL-12. Optionally, IL-12 may be mutein. IL-12 mutein may be aglycosylated or partially aglycosylated.

The invention relates to the technical field of molecular biology, in particular to a molecular marker combination and a kit for B lymphoma cell detection or enrichment or PVRL prediction, diagnosis or prognosis, and B lymphoma cells are tumor cells of primary vitreoretinal lymphoma. Specifically, the invention provides a molecular marker combination capable of being used for detecting tumor cells of primary vitreous retinal lymphoma, and the molecular marker combination comprises ZBTB7A and CDKN2A.

The invention discloses a composition for treating ABC type diffuse large B-cell lymphoma and application of the composition, and relates to the technical field of biological medicine. The composition comprises the chidamide and the hispidulin. According to the invention, a synergistic treatment system of the composition chidamide and hispidulin is constructed, and the problem of treatment of ABC type diffuse large B-cell lymphoma is accurately solved. According to the composition, through targeting double key targets of HDAC3 and PIM1, the synergistic interaction of epigenetic regulation and signal channel inhibition is realized, and the anti-tumor effect is remarkably improved. The invention successfully breaks through the bottleneck that the existing R-CHOP scheme is poor in curative effect and easy to relapse in the treatment of ABC subtype lymphoma, provides a brand new high-specificity treatment strategy for relapse or refractory ABC type diffuse large B-cell lymphoma, and has a wide clinical application prospect.

The application discloses a compound capable of targeted degradation of MYC and application thereof, and belongs to the technical field of medicines. The compound can target degradation of MYC after entering a patient's body, thereby effectively inhibiting the proliferation of tumor cells such as lymphoma and osteosarcoma and cancer cells such as colorectal cancer, and having good anti-tumor effect and anticancer effect; the compound can also inhibit the proliferation of myelomonocytic leukemia cells in the patient's body, thereby providing a new treatment scheme for treating myelomonocytic leukemia; the compound has a synergistic effect when combined with doxorubicin, has better anti-tumor activity, and has a wide application prospect in the field of medicines.

The invention discloses an interferon regulatory factor 4 (IRF4) inhibitor as shown in a formula (1) and a preparation method thereof, and a target product is prepared by taking dinorhydrin as a raw material through reactions such as TBS protection, 4, 4-dimethylation, TBS protection removal, oxidation, esterification, reduction, iodination, cyano substitution, Wittig, hydrolysis, esterification, amidation, condensation and the like. The invention further discloses an application of the IRF4 inhibitor in the aspect of treating multiple myeloma (MM), and further discloses an application of the IRF4 inhibitor in the aspect of treating multiple myeloma (MM). The compound can selectively inhibit the multiplication capacity of IRF4 high-expression myeloma cells, and has a good application prospect in treatment of IRF4 high-expression tumors such as multiple myeloma and lymphoma.

The application relates to a kind of automatic classification methods of children lymphoma type based on imageomics, belong to artificial intelligence technical field.It includes the following steps: collecting children lymphoma CT image, constructs data set;The original three-dimensional CT image is preprocessed and adaptively gray window is adjusted, and preprocessed three-dimensional CT image data is obtained;Imageomics feature extraction and region perception gradient weighted screening are carried out, and the comprehensive screening score of each feature is obtained;A classification model of children lymphoma type is constructed, the enhanced imageomics feature, the clinical prior feature and the deep feature modulated by region perception weight are fused, the adaptive fusion of features is realized by using dynamic gating mechanism, and the category probability vector is output;The model is trained and optimized by a composite loss function, and a trained model is obtained;The CT image of children lymphoma to be classified is input into the trained model, and a classification result is obtained.The application can improve the accuracy of automatic classification of children lymphoma type.

The application belongs to the technical field of medical image processing and computer-aided diagnosis, and discloses an orbital lymphoma and inflammatory pseudotumor classification method, system, device and terminal, in the obtained orbital DCE-MRI image, the tumor region and the eye cone triangular region in the original image are manually segmented and pretreated; the neural network is used for extracting the features of the tumor region, and the features are subjected to clustering statistical analysis as the tumor region features; the eye cone triangular region is subjected to feature extraction as a similarity judgment standard, and the self-classification and self-recovery network is used for extracting the eye cone region features; the original image is used as the input network and combined with the features of the tumor region and the eye cone triangular region to train the network model; the multi-modal orbital data is input into the classification model for processing, so that the orbital lymphoma and inflammatory pseudotumor are classified. The application comprehensively considers the texture features of the tumor and the depth features of the eye cone region, effectively improves the prediction accuracy, and has the characteristics of high accuracy.

The application relates to the fields of biotechnology and targeted therapy, and particularly relates to a recombinant construct, a CAR-T cell and construction and application thereof. The application verifies the role and mechanism of THEMIS in maintaining the long-term killing of tumor cells of CAR-T through experiments. The CAR-T cell overexpressing THEMIS is constructed, compared with a control group, the proliferation capacity and memory cell formation capacity of the THEMIS-7x19 CAR-T cell are enhanced after antigen stimulation, and the cytokines are in a controllable state, the cell apoptosis and exhaustion are reduced, and the long-term tumor killing capacity can be maintained more effectively. The in-vivo experiment also proves that the THEMIS-7x19 CAR-T cell has stronger anti-tumor effect compared with the control group in a lymphoma tumor-bearing mouse model, and the survival time of the mouse is significantly prolonged.

The application belongs to the field of intelligent medical treatment, and particularly relates to an artificial intelligence feature extraction method and system based on lymphoma MICM phenotyping. The method comprises the following steps: S1, obtaining a diagnosis report of a to-be-tested person; S2, obtaining a structured diagnosis report based on the diagnosis report; S3, vectorizing the structured diagnosis report to obtain a vectorized diagnosis report; S4, inputting the vectorized diagnosis report into a quantum coding-based Transformer for feature extraction to obtain MICM phenotyping features; the quantum coding-based Transformer converts input data into a quantum state and extracts quantum state feature information, and converts the quantum state feature information into non-quantum state data and outputs the MICM phenotyping features. The application extracts the required MICM features by using the quantum coding-based Transformer, and enhances the data feature capturing capacity of the model by using the quantum coding-based Transformer algorithm.

The objective of the present invention is to treat cancer in affected dogs by using interleukin-15, which plays a pivotal role in both innate immunity and acquired immunity. Specifically, the present invention relates to a composition for treating cancer in mammary tumor- or lymphoma-affected dogs, or an anticancer immune enhancer, comprising recombinant canine interleukin-15. The present invention also relates to the dosage and use of recombinant canine interleukin-15 in the treatment of cancer in mammary tumor- or lymphoma-affected dogs. The present invention can exhibit therapeutically effective anticancer- or anticancer immunity-enhancing efficacy by minimizing harmful effects or side effects after standard treatment in mammary tumor- or lymphoma-affected dogs by using recombinant canine interleukin-15.

Disclosed is a class of multi-branched drug conjugates capable of specifically targeting CD44. The class of compounds specifically binds to CD44, and may target tumor cells and tissues having high expression of CD44, so that the concentration of the conjugate in a target tissue is high, the clinical treatment effect thereof is improved, and toxicity is reduced. The compound of the present invention is suitable for treating all tumors having high expression of CD44, comprising but not limited to gastric cancer, pancreatic cancer, small cell lung cancer, colon cancer, breast cancer, lung adenocarcinoma, liver cancer, nasopharyngeal carcinoma, malignant glioma, lymphoma, renal carcinoma, ovarian cancer, head and neck cancer, squamous cell carcinoma, and the like.

The present disclosure provides anti-CD180 binding molecules and uses thereof. In one embodiment, the anti-CD180 binding molecule is an anti-CD180 antibody. Also provided is an anti-CD180 antibody-drug conjugate (ADC) comprising a monoclonal antibody or antigen-binding fragment thereof that targets CD180-highly expressing tumors, a cytotoxic drug payload, and a linker moiety that conjugates the antibody or antigen-binding fragment thereof that targets CD180-highly expressing tumors to the cytotoxic drug payload. The anti-CD180 antibody or antigen-binding fragment thereof, and the ADC comprising the anti-CD180 antibody or antigen-binding fragment thereof, are useful in treating diseases such as acute myeloid leukemia, mantle cell lymphoma, multiple myeloma, follicular lymphoma, acute B-lymphoblastic leukemia, or diffuse large B-cell lymphoma.

The present application relates to the technical field of drug synthesis, in particular to a benzylurea compound, a preparation method and application thereof. The structural formula of the benzylurea compound is shown in the following: wherein R1 represents any one of a connecting bond, a substituted or unsubstituted amide bond and a C1-C10 unsubstituted alkyl bond, and R2 is selected from any one of a substituted or unsubstituted single aromatic heterocyclic group, or a substituted or unsubstituted single aromatic ring group, or a substituted or unsubstituted benzo-fused ring group. The benzylurea compound can effectively inhibit the activity of tumor cells, and has a good therapeutic effect on esophageal cancer, lung cancer, gastric cancer, breast cancer, colorectal cancer, laryngeal cancer, nasopharyngeal cancer, oral cancer, pancreatic cancer, renal cancer, prostate cancer, bladder cancer, cervical cancer, lymphoma, acute leukemia, osteosarcoma, Ewing's sarcoma and thyroid cancer.

IL2-CCR4 bispecific immunotoxin, CCR4-IL2 bispecific immunotoxin, and methods of use thereof for treatment of refractory and recurrent human CD25.sup.+ and / or CCR4.sup.+ cutaneous T cell lymphoma, and other human CD25.sup.+ or CCR4.sup.+ tumors. The bispecific immunotoxin can be also used for broad cancer treatment via depleting CD25.sup.+ or CCR4.sup.+ Tregs.

The present invention provides pharmaceutical compositions and methods of use of bisbenzylisoquinoline, e.g., 6,6',7,12-tetramethoxy-2,2'-dimethyl-berbaman, and analogs, derivatives, isomers, and modified forms of the compound, e.g., in crystalline, salt, or salt form, in combination with pharmaceutically acceptable acids or other agents, for the treatment of acute, chronic, and preleukemic conditions, as well as lymphoma and solid tumors. These include, but are not limited to, preneoplastic and neoplastic diseases and solid tumors, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), atypical chronic myeloid leukemia (aCML), and acute myeloid leukemia (AML), polycythemia vera (PV), chronic lymphoblastic leukemia (CLL), myeloproliferative syndrome (MPS), myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN), myelofibrosis (MF), and polycythemia vera (PV).

The invention provides a polypeptide or a pharmaceutically acceptable salt thereof. The polypeptide has an amino acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 2. The polypeptide or the pharmaceutically acceptable salt of the polypeptide can be combined with PD-1 and CTLA-4, and is used for effectively inhibiting the PD-1 and the CTLA-4. Therefore, the polypeptide or the pharmaceutically acceptable salt thereof can be used for detecting PD-1 and / or CTLA-4, and can also be used for treating or preventing PD-1 and / or CTLA-4 mediated diseases (such as tumors or cancers, such as non-small cell lung cancer, melanoma, lymphoma, leukemia and other diseases).

The application discloses a CAR-T treatment response intelligent prediction system based on medical images, relates to the fields of medical image analysis and tumor immunotherapy, and comprises a data integration module, a multi-modal feature extraction module, a prediction model construction module, a model optimization module, a clinical analysis module and an adverse reaction risk early warning module. The system integrates PET-CT, MRI, ultrasound and other multi-modal medical image data, extracts the shape, texture and metabolic characteristics of tumors, adopts a three-dimensional convolutional neural network to construct a treatment response prediction model, innovatively applies differential geometry theory to construct a medical image manifold structure and generate tumor adversarial samples that maintain topological characteristics, executes an adaptive optimization strategy by using a Riemann metric space, realizes accurate prediction of the CAR-T treatment response of lymphoma patients, and performs adverse reaction risk early warning through brain and organ image analysis.

The present disclosure provides a chimeric antigen receptor (CAR) polypeptide comprising a CD74 antigen binding domain, a transmembrane domain, an intracellular signaling domain, and a co-stimulatory signaling region. Also provided herein is an isolated nucleic acid encoding a recombinant polypeptide as disclosed herein, a vector comprising the isolated nucleic acid, and a cell comprising the vector. Also provided herein is a method of treating lymphoma in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a chimeric antigen receptor polypeptide as disclosed herein. Also described herein is a method of reducing tumor activity in a subject having lymphoma comprising administering to the subject a therapeutically effective amount of a chimeric antigen receptor polypeptide as described herein.

The invention discloses an external plaster for treating lymphoma, which is prepared from the following materials in parts by weight: 10-20 parts of aconitum carmichaeli, 5-20 parts of moutan bark, 15-30 parts of sculellaria barbata, 10-25 parts of astragalus membranaceus, 8-15 parts of semen momordicae, 5-10 parts of musk, 10-25 parts of oldenlandia diffusa, 5-10 parts of cantharides, 8-12 parts of centipede, 3-10 parts of borneol, 5-10 parts of gecko and a mixed adhesive. Comprising the steps of grinding, soaking, heating, stirring and precipitating. The external plaster for treating lymphoma prepared by the method has the characteristics of low preparation cost and obvious targeted treatment effect, and plays a great role in traditional medical treatment for patients.

The present application provides a polypeptide or a pharmaceutically acceptable salt thereof, wherein the polypeptide has an amino acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 2. The polypeptide or the pharmaceutically acceptable salt thereof can bind to PD-1 and CTLA-4, and is used for effectively inhibiting PD-1 and CTLA-4. Thus, the polypeptide or the pharmaceutically acceptable salt thereof can be used for detecting PD-1 and / or CTLA-4, and can also be used for treating or preventing diseases mediated by PD-1 and / or CTLA-4 (such as tumors or cancers, for example, non-small cell lung cancer, melanoma, lymphoma and leukemia, etc.).

This invention discloses an antitumor compound, its preparation method, and its uses, belonging to the field of pharmaceutical technology, and specifically relating to a class of compounds with specific chemical structures possessing antitumor activity. The compound is a 6'-phenyl-2'H-spiro[cyclohexane-1,1'-isoquinoline]-3'(4'H)-one compound, with the structure shown in general formula (I) or (II): or, where R is a monosubstituted hydrogen atom, chlorine atom, methoxy atom, or fluorine atom at different positions on the benzene ring. This invention demonstrates the compound's tumor-inhibiting activity based on tumor cell line testing, specifically human diffuse large B-cell lymphoma cells. The compound provided by this invention uses readily available raw materials, and experiments have shown it to have good anticancer effects, demonstrating promising application prospects in the design and development of antitumor drugs.

This invention provides a method for constructing an extranodal lymphoma pathology database, comprising: Step 1: determining a list of lymphoma subtypes to be included in the database based on the classification criteria for tumors of the lymphatic and hematopoietic systems; Step 2: generating a lymphoma subtype data package by obtaining at least a preset number of target cases for each lymphoma subtype according to the lymphoma subtype query list, wherein the target cases contain various clinical information; Step 3: storing the lymphoma subtype data package to establish an extranodal lymphoma pathology database. This invention establishes a digital slide library for extranodal lymphoma pathology, allowing medical students to search digital pathology knowledge graphs, retrieve digital pathology images related to pathology teaching text content, and view images with detailed clinical information. The library also automatically displays the differences between normal images and images with detailed annotations of lesions, allowing students to highlight key points and save notes, facilitating their pathology learning and improving learning efficiency.